These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

759 related items for PubMed ID: 21787319

  • 1. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C.
    Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
    [Abstract] [Full Text] [Related]

  • 2. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?
    Hölscher C, Li L.
    Neurobiol Aging; 2010 Sep; 31(9):1495-502. PubMed ID: 18930564
    [Abstract] [Full Text] [Related]

  • 3. The role of GLP-1 in neuronal activity and neurodegeneration.
    Hölscher C.
    Vitam Horm; 2010 Sep; 84():331-54. PubMed ID: 21094907
    [Abstract] [Full Text] [Related]

  • 4. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.
    Duffy AM, Hölscher C.
    Neuroscience; 2013 Jan 03; 228():294-300. PubMed ID: 23103794
    [Abstract] [Full Text] [Related]

  • 5. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL, Hölscher C.
    Neuropharmacology; 2014 Jan 03; 76 Pt A():57-67. PubMed ID: 23973293
    [Abstract] [Full Text] [Related]

  • 6. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
    Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, Brock B, Rungby J.
    Expert Opin Ther Targets; 2011 Oct 03; 15(10):1153-62. PubMed ID: 21749267
    [Abstract] [Full Text] [Related]

  • 7. [Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease].
    Wang XH, Yang W, Qi JS.
    Sheng Li Xue Bao; 2010 Oct 25; 62(5):398-406. PubMed ID: 20945041
    [Abstract] [Full Text] [Related]

  • 8. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.
    Abbas T, Faivre E, Hölscher C.
    Behav Brain Res; 2009 Dec 14; 205(1):265-71. PubMed ID: 19573562
    [Abstract] [Full Text] [Related]

  • 9. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.
    Hölscher C.
    Alzheimers Dement; 2014 Feb 14; 10(1 Suppl):S47-54. PubMed ID: 24529525
    [Abstract] [Full Text] [Related]

  • 10. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.
    Hölscher C.
    Biochem Soc Trans; 2014 Apr 14; 42(2):593-9. PubMed ID: 24646283
    [Abstract] [Full Text] [Related]

  • 11. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.
    Tai J, Liu W, Li Y, Li L, Hölscher C.
    Brain Res; 2018 Jan 01; 1678():64-74. PubMed ID: 29050859
    [Abstract] [Full Text] [Related]

  • 12. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
    Hölscher C.
    Sheng Li Xue Bao; 2014 Oct 25; 66(5):497-510. PubMed ID: 25331995
    [Abstract] [Full Text] [Related]

  • 13. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N, García-Arnés JA, Gómez-Huelgas R, Valdivielso-Felices P, García-Arias C, González-Santos P.
    Rev Neurol; 2014 Dec 01; 59(11):517-24. PubMed ID: 25418147
    [Abstract] [Full Text] [Related]

  • 14. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
    Holscher C.
    Recent Pat CNS Drug Discov; 2010 Jun 01; 5(2):109-17. PubMed ID: 20337586
    [Abstract] [Full Text] [Related]

  • 15. New animal models of Alzheimer's disease that display insulin desensitization in the brain.
    Gao C, Liu Y, Li L, Hölscher C.
    Rev Neurosci; 2013 Jun 01; 24(6):607-15. PubMed ID: 24259244
    [Abstract] [Full Text] [Related]

  • 16. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
    McClean PL, Hölscher C.
    Neuropharmacology; 2014 Nov 01; 86():241-58. PubMed ID: 25107586
    [Abstract] [Full Text] [Related]

  • 17. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
    Hölscher C.
    Expert Opin Investig Drugs; 2020 Apr 01; 29(4):333-348. PubMed ID: 32175781
    [Abstract] [Full Text] [Related]

  • 18. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.
    Hölscher C.
    CNS Drugs; 2012 Oct 01; 26(10):871-82. PubMed ID: 22938097
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.